Haemonetics (NYSE:HAE) Announces Earnings Results

Haemonetics (NYSE:HAE) posted its quarterly earnings data on Thursday. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01), Zacks reports. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. Haemonetics updated its FY 2025 guidance to 4.500-4.700 EPS.

Haemonetics Trading Down 11.6 %

NYSE HAE traded down $8.29 during trading on Thursday, hitting $62.95. 3,466,641 shares of the company’s stock traded hands, compared to its average volume of 873,047. The stock has a fifty day moving average of $77.44 and a two-hundred day moving average of $78.73. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09. Haemonetics has a 12-month low of $61.43 and a 12-month high of $97.97. The firm has a market cap of $3.16 billion, a P/E ratio of 26.12, a PEG ratio of 1.07 and a beta of 0.39.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Raymond James upgraded Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price objective for the company in a report on Friday, November 8th. JPMorgan Chase & Co. began coverage on Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $112.00 price objective on shares of Haemonetics in a research report on Tuesday, December 3rd. Finally, Barrington Research reiterated an “outperform” rating and set a $108.00 target price on shares of Haemonetics in a research note on Wednesday, December 4th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $108.78.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.